Global Antiemetics Market Size Study & Forecast, by Drug Type (Antihistamines, Serotonin Receptor Antagonists, Dopamine Receptor Antagonists, Neurokinin Receptor Antagonists, Anticholinergics, Other Drug Types), by Application (Chemotherapy, Post Operativ

Global Antiemetics Market Size Study & Forecast, by Drug Type (Antihistamines, Serotonin Receptor Antagonists, Dopamine Receptor Antagonists, Neurokinin Receptor Antagonists, Anticholinergics, Other Drug Types), by Application (Chemotherapy, Post Operative Surgery, Pregnancy and Gatroenteritis, Other Applications), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), and Regional Analysis, 2023-2030

Global Antiemetics Market is valued at approximately USD 2.44 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.1% over the forecast period 2023-2030. Antiemetics is a group of drugs used to treat or prevent nausea and vomiting, which are frequent side effects of many different medical illnesses, treatments, and drugs. An antiemetic is a type of medication that lessens nausea and vomiting. The adverse effects of opioid analgesics, general anesthetics, and chemotherapy are frequently treated with them. It is used to treat conditions including motion sickness, pregnancy, food poisoning, and dizziness in patients. The growing prevalence of nausea and vomiting, surge in research and development activities and identification of new drug targets, increasing healthcare expenditure, and rising health consciousness among people, coupled with the rising number of hospitals are the key factors that are associated with the market growth during the estimated period.

The increasing prevalence of cancer and gastroenteritis worldwide is playing a vital role in bolstering the market demand across the globe. Chemotherapy and radiation therapy are standard treatments for cancer. However, these treatments often cause significant nausea and vomiting as side effects. The increasing adoption of these therapies, along with the need to effectively manage treatment-related symptoms, drives the demand for antiemetic medications. The GLOBOCAN stated that, in 2020, it was estimated that approximately 19.3 million new cases of cancer were reported globally and the figure is anticipated to rise to 30.2 million by 2040. Thus, these aforementioned factors are propelling the growth of the Antiemetics Market during the estimated period. Moreover, the rising technological advancements in drug delivery systems, as well as the expanded use of antiemetics in non-oncology settings present various lucrative opportunities over the forecast years. However, the less awareness about antiemetic drugs among the population and the unavailability of suitable animal models are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Antiemetics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising inclination towards chemotherapy and radiation therapy, increasing focus on advancements in antiemetic drug development, and the presence of well-established market players. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The growing geriatric population, increasing prevalence of nausea and vomiting, and expanded use of antiemetics in non-oncology settings are significantly propelling the market demand across the region.

Major market players included in this report are:
Novartis AG
GlaxoSmithKline Plc
Cipla Limited
Acacia Pharma Group Plc
Dr. Reddy’s Laboratories Ltd
Sanofi
Merck & Co. Inc
Pfizer Inc
Torrent Pharmaceuticals Ltd
Johnson & Johnson Private Limited

Recent Developments in the Market:
In February 2020, The US FDA approved Barhemsys from Acacia Pharmaceutical. A formulation of amisulpride (a dopamine antagonist) for intravenous administration is used to treat postoperative nausea and vomiting in individuals who failed to improve after receiving therapy with an antiemetic from a different class. Barhemsys is anticipated to go on sale in the second half of 2022, as the business is already making such preparations.

Global Antiemetics Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Drug Type, Application, Distribution Channel, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drug Type:
Antihistamines
Serotonin Receptor Antagonists
Dopamine Receptor Antagonists
Neurokinin Receptor Antagonists
Anticholinergics
Other Drug Types

By Application:
Chemotherapy
Post Operative Surgery
Pregnancy and Gatroenteritis
Other Applications

By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa




Companies Mentioned
Novartis AG
GlaxoSmithKline Plc
Cipla Limited
Acacia Pharma Group Plc
Dr. Reddy’s Laboratories Ltd
Sanofi
Merck & Co. Inc
Pfizer Inc
Torrent Pharmaceuticals Ltd
Johnson & Johnson Private Limited

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.